New Review Questions Alzheimer’s Drugs
A recent review by Cochrane has raised concerns about the safety and effectiveness of Alzheimer’s drugs that target amyloid proteins. This review has sparked discussion among experts and pharmaceutical companies, some of whom disagree with the findings.
These drugs, often monoclonal antibodies, aim to reduce a protein called amyloid-beta, which can form sticky plaques in the brains of Alzheimer’s patients. The review looked at data from 17 clinical trials involving over 20,000 participants with mild cognitive impairment or early-stage Alzheimer’s disease.
While earlier studies suggested that these amyloid-targeting drugs could slow the progression of Alzheimer’s, the Cochrane review concluded that their effects on memory decline and overall dementia severity were either negligible or very small.
Lead author Francesco Nonino, a neurologist from Italy, expressed disappointment, saying, “Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients.” He emphasized the importance of distinguishing between statistically significant results and clinically meaningful benefits.
The review also pointed out potential risks associated with these treatments, such as an increased chance of brain swelling and bleeding. Although some changes were noted in brain scans, these did not always correspond to noticeable symptoms, raising questions about the long-term effects of the drugs.
The researchers concluded that simply lowering amyloid-beta levels is unlikely to lead to significant improvements in patients’ conditions. While the drugs may reduce amyloid in the brain, this has not translated into improved outcomes for patients.
Experts Call for New Approaches
Edo Richard, a senior author from Radboud University, highlighted the urgency for more effective treatments. He noted that currently approved medications do offer some benefits but there is a significant need for better solutions. “Given the lack of correlation between amyloid removal and clinical improvement, we need to explore other ways to tackle this challenging disease,” he said.
In light of this review, the Alzheimer’s Association has urged Cochrane to reconsider its analysis, calling it “scientifically flawed” and a potential source of confusion. They argue that the review does not adequately reflect the experiences of patients, who report real-world benefits from these drugs.
Lilly, the company behind the Alzheimer’s drug donanemab, has also expressed concerns about the review’s methodology. A spokesperson stated that it combines data from multiple therapies that did not meet clinical trial goals and were never approved, which undermines the overall conclusions drawn.
On a positive note, the Alzheimer’s Association pointed to evidence from clinical settings where these treatments have shown meaningful results and acceptable side effects.
Future Directions
The researchers behind the review acknowledged the limitations of their analysis, noting that the benefits might vary among different patient groups. They called for more research into other biological pathways involved in Alzheimer’s to find effective treatments.
As the search for better Alzheimer’s therapies continues, many patients and their families hope for promising new developments.
